Shida Yan, Xing Zhang, Fengjiao Li, Ankui Yang, Hui Li, Wanming Hu, Qiaohong Lin, Xiyuan Li, Mingyuan Du, Jingtao Chen, Guodong Man, Jianwei Zhang, Xuemei Fang, Li Ning, Shiting Zhang, Lili Han, Yanmei Ma, Jun Wang, Shuwei Chen, Ming Song
{"title":"新辅助辛替单抗和化疗后经口手术治疗hpv阳性可切除口咽癌：单臂，双中心，2期试验。","authors":"Shida Yan, Xing Zhang, Fengjiao Li, Ankui Yang, Hui Li, Wanming Hu, Qiaohong Lin, Xiyuan Li, Mingyuan Du, Jingtao Chen, Guodong Man, Jianwei Zhang, Xuemei Fang, Li Ning, Shiting Zhang, Lili Han, Yanmei Ma, Jun Wang, Shuwei Chen, Ming Song","doi":"10.1016/j.eclinm.2025.103393","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment deintensification, such as neoadjuvant immunochemotherapy and transoral surgery, has shown promise but remains under investigation in human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV<sup>+</sup>OPSCC). We aimed to explore the efficacy and safety of neoadjuvant immunochemotherapy and the feasibility of sequential transoral surgery in patients with resectable HPV<sup>+</sup>OPSCC.</p><p><strong>Methods: </strong>In this single-arm, two-centre, phase 2 trial, patients with resectable HPV<sup>+</sup>OPSCC (clinical stage T2-4N0-3M0) were recruited and received two cycles of neoadjuvant sintilimab, cisplatin, and nab-paclitaxel every three weeks, followed by transoral surgery, including transoral robotic surgery (TORS). The primary endpoint was major pathological response (MPR), defined as the residual viable tumor of less than or equal to 10% in the primary lesion. The study is registered with Chinese Clinical Trial Registry (ChiCTR2200058650) and is ongoing.</p><p><strong>Findings: </strong>Between April 13, 2022 and November 17, 2023, 27 patients were enrolled and all received two cycles of neoadjuvant immunochemotherapy, which all achieved partial responses. Among them, 25 patients received radical surgery (21 TORSs and 4 transoral surgeries). MPR was achieved in 24 patients (24/25, 96.0%), including 17 (17/25, 68.0%) with pathological complete response (pCR). Grade 1-2 treatment-related adverse events (TRAE) occurred in 24 of 27 patients (88.9%), including skin rash (12/27, 44.4%), alopecia (10/27, 37.0%), nausea (8/27, 29.6%), fatigue (8/27, 29.6%), and pain (8/27, 29.6%). Only one patient (1/27, 3.7%) experienced grade 3 TRAEs with no treatment-related death. For the per-protocol population, the 2-year DFS and OS were both 96.0% (95% CI: 88.6%-100.0%). Most patients experienced improved symptoms including pain and swallowing at 3 months post-surgery, and remained stable at 6 months and 1 year post-surgery. Circulating tumor HPV-DNA clearance had a trend to occur in patients with pCR.</p><p><strong>Interpretation: </strong>Neoadjuvant immunochemotherapy and sequential transoral surgery, including TORS, appears to be a feasible strategy that yields favorable oncologic and functional outcomes for patients with resectable HPV<sup>+</sup>OPSCC.</p><p><strong>Funding: </strong>Innovent Biologics.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"86 ","pages":"103393"},"PeriodicalIF":10.0000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329559/pdf/","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant sintilimab and chemotherapy followed by transoral surgery for HPV-positive resectable oropharyngeal cancer: a single-arm, two-centre, phase 2 trial.\",\"authors\":\"Shida Yan, Xing Zhang, Fengjiao Li, Ankui Yang, Hui Li, Wanming Hu, Qiaohong Lin, Xiyuan Li, Mingyuan Du, Jingtao Chen, Guodong Man, Jianwei Zhang, Xuemei Fang, Li Ning, Shiting Zhang, Lili Han, Yanmei Ma, Jun Wang, Shuwei Chen, Ming Song\",\"doi\":\"10.1016/j.eclinm.2025.103393\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Treatment deintensification, such as neoadjuvant immunochemotherapy and transoral surgery, has shown promise but remains under investigation in human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV<sup>+</sup>OPSCC). We aimed to explore the efficacy and safety of neoadjuvant immunochemotherapy and the feasibility of sequential transoral surgery in patients with resectable HPV<sup>+</sup>OPSCC.</p><p><strong>Methods: </strong>In this single-arm, two-centre, phase 2 trial, patients with resectable HPV<sup>+</sup>OPSCC (clinical stage T2-4N0-3M0) were recruited and received two cycles of neoadjuvant sintilimab, cisplatin, and nab-paclitaxel every three weeks, followed by transoral surgery, including transoral robotic surgery (TORS). The primary endpoint was major pathological response (MPR), defined as the residual viable tumor of less than or equal to 10% in the primary lesion. The study is registered with Chinese Clinical Trial Registry (ChiCTR2200058650) and is ongoing.</p><p><strong>Findings: </strong>Between April 13, 2022 and November 17, 2023, 27 patients were enrolled and all received two cycles of neoadjuvant immunochemotherapy, which all achieved partial responses. Among them, 25 patients received radical surgery (21 TORSs and 4 transoral surgeries). MPR was achieved in 24 patients (24/25, 96.0%), including 17 (17/25, 68.0%) with pathological complete response (pCR). Grade 1-2 treatment-related adverse events (TRAE) occurred in 24 of 27 patients (88.9%), including skin rash (12/27, 44.4%), alopecia (10/27, 37.0%), nausea (8/27, 29.6%), fatigue (8/27, 29.6%), and pain (8/27, 29.6%). Only one patient (1/27, 3.7%) experienced grade 3 TRAEs with no treatment-related death. For the per-protocol population, the 2-year DFS and OS were both 96.0% (95% CI: 88.6%-100.0%). Most patients experienced improved symptoms including pain and swallowing at 3 months post-surgery, and remained stable at 6 months and 1 year post-surgery. Circulating tumor HPV-DNA clearance had a trend to occur in patients with pCR.</p><p><strong>Interpretation: </strong>Neoadjuvant immunochemotherapy and sequential transoral surgery, including TORS, appears to be a feasible strategy that yields favorable oncologic and functional outcomes for patients with resectable HPV<sup>+</sup>OPSCC.</p><p><strong>Funding: </strong>Innovent Biologics.</p>\",\"PeriodicalId\":11393,\"journal\":{\"name\":\"EClinicalMedicine\",\"volume\":\"86 \",\"pages\":\"103393\"},\"PeriodicalIF\":10.0000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329559/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EClinicalMedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.eclinm.2025.103393\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2025.103393","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Neoadjuvant sintilimab and chemotherapy followed by transoral surgery for HPV-positive resectable oropharyngeal cancer: a single-arm, two-centre, phase 2 trial.
Background: Treatment deintensification, such as neoadjuvant immunochemotherapy and transoral surgery, has shown promise but remains under investigation in human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+OPSCC). We aimed to explore the efficacy and safety of neoadjuvant immunochemotherapy and the feasibility of sequential transoral surgery in patients with resectable HPV+OPSCC.
Methods: In this single-arm, two-centre, phase 2 trial, patients with resectable HPV+OPSCC (clinical stage T2-4N0-3M0) were recruited and received two cycles of neoadjuvant sintilimab, cisplatin, and nab-paclitaxel every three weeks, followed by transoral surgery, including transoral robotic surgery (TORS). The primary endpoint was major pathological response (MPR), defined as the residual viable tumor of less than or equal to 10% in the primary lesion. The study is registered with Chinese Clinical Trial Registry (ChiCTR2200058650) and is ongoing.
Findings: Between April 13, 2022 and November 17, 2023, 27 patients were enrolled and all received two cycles of neoadjuvant immunochemotherapy, which all achieved partial responses. Among them, 25 patients received radical surgery (21 TORSs and 4 transoral surgeries). MPR was achieved in 24 patients (24/25, 96.0%), including 17 (17/25, 68.0%) with pathological complete response (pCR). Grade 1-2 treatment-related adverse events (TRAE) occurred in 24 of 27 patients (88.9%), including skin rash (12/27, 44.4%), alopecia (10/27, 37.0%), nausea (8/27, 29.6%), fatigue (8/27, 29.6%), and pain (8/27, 29.6%). Only one patient (1/27, 3.7%) experienced grade 3 TRAEs with no treatment-related death. For the per-protocol population, the 2-year DFS and OS were both 96.0% (95% CI: 88.6%-100.0%). Most patients experienced improved symptoms including pain and swallowing at 3 months post-surgery, and remained stable at 6 months and 1 year post-surgery. Circulating tumor HPV-DNA clearance had a trend to occur in patients with pCR.
Interpretation: Neoadjuvant immunochemotherapy and sequential transoral surgery, including TORS, appears to be a feasible strategy that yields favorable oncologic and functional outcomes for patients with resectable HPV+OPSCC.
期刊介绍：
eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
